Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics Inc. (ANGO) develops minimally invasive medical devices for oncology, vascular, and surgical treatments. This page aggregates official news and press releases about product innovations, financial performance, and strategic initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study results, and market expansions. Content spans earnings announcements, technology partnerships, and FDA clearances relevant to interventional radiology and cancer treatment advancements.
All materials are sourced directly from the company and reputable financial publications. Bookmark this page for structured access to ANGO's evolving role in medical device innovation without promotional bias.
AngioDynamics (NASDAQ: ANGO) reported its Q3 FY2025 financial results with pro forma net sales of $72.0 million, up 9.2% year-over-year. The company's MedTech segment showed strong performance with $31.3 million in sales, growing 22.2%, while MedDevice sales reached $40.7 million, up 0.9%.
Key highlights include GAAP gross margin of 54.0%, a loss per share of $(0.11), and adjusted EBITDA of $1.3 million. The company received FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation and initiated the AMBITION BTK trial for the Auryon Atherectomy System.
AngioDynamics increased its FY2025 guidance, now expecting net sales of $285-288 million, MedTech sales growth of 14-16%, gross margin of 53-54%, and adjusted EBITDA of $4.0-5.0 million. The company secured a $25.0 million revolving credit line with J.P. Morgan for additional financial flexibility.
AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has announced a virtual cardiovascular investor event scheduled for Wednesday, April 2, 2025.
The event will commence at 9:00 AM ET, immediately following the company's Fiscal 2025 Third Quarter Financial Results Conference Call at 8:00 AM ET. During this 60-minute session, AngioDynamics will provide an in-depth exploration of their cardiovascular technology portfolio and strategic vision.
Investors can access the webcast through the company's website at www.angiodynamics.com under the 'Investors' section or via the provided registration link.
AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has announced its upcoming fiscal 2025 third quarter financial results release scheduled for April 2, 2025, before market open.
The company will host two key events on the same day: a financial results conference call at 8:00 AM ET, followed by a virtual cardiovascular investor event at 9:00 AM ET. The latter will provide an in-depth look at the company's cardiovascular technology portfolio and strategic vision.
Investors can participate in the conference call through domestic (1-877-407-0784) or international (+1-201-689-8560) dial-in numbers. Both events will be accessible via webcast through the company's investor relations website. A replay of the call will be available until April 09, 2025, using passcode 13752371.
AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment solutions, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference.
The company's leadership team, including President and CEO Jim Clemmer and EVP/CFO Stephen Trowbridge, will deliver a presentation on Monday, March 17, 2025, at 12:00 p.m. ET. Investors and interested parties can access the live webcast through the 'Investors' section of AngioDynamics' website at www.angiodynamics.com, with a replay option available after the event.
AngioDynamics (NASDAQ: ANGO) has launched the AMBITION BTK study, a multicenter randomized controlled trial evaluating their Auryon Atherectomy System in treating critical limb ischemia. The trial will compare the system combined with standard balloon angioplasty versus angioplasty alone for infrapopliteal lesions.
The study will enroll up to 200 subjects across 30 hospital-based sites, with an additional registry tracking up to 1,500 subjects. The Auryon laser system, which has already treated over 100,000 patients worldwide, can treat various infrainguinal lesion types including above-the-knee, below-the-knee, and in-stent restenosis.
This initiative builds on previous successful trials where the system effectively treated 61 complex calcified lesions in 60 patients across four U.S. centers. The technology uses a 355nm wavelength laser platform that enables targeted treatment of peripheral artery disease while minimizing perforation risks.
AngioDynamics (NASDAQ: ANGO) announced the publication of the APEX-AV trial results in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI). The trial evaluated the AlphaVac F1885 System for treating acute intermediate-risk pulmonary embolism (PE). Results showed a 35.5% reduction in clot burden and significant reduction in RV/LV ratio with low adverse event rates. The study, involving 122 patients across 25 sites, demonstrated the device's safety and efficacy. The trial was conducted in partnership with the PERT Consortium and led by Dr. William Brent Keeling and Dr. Mona Ranade. The device's unique features, such as its funnel tip and optional wireless navigation, contributed to its success. The AlphaVac F1885 System received FDA clearance in April 2024.
AngioDynamics (NASDAQ: ANGO) reported its Q2 FY2025 financial results, showing notable growth in its Med Tech segment. The company achieved net sales of $73.0 million, representing a 9.2% year-over-year increase. Med Tech net sales grew 25.0% to $31.5 million, while Med Device sales slightly decreased by 0.4% to $41.5 million.
Key highlights include FDA 510(k) clearance for NanoKnife Prostate Tissue Ablation and receipt of CPT Category I Codes for Irreversible Electroporation (IRE). The company reported a GAAP loss per share of $(0.26) and adjusted loss per share of $(0.04), with adjusted EBITDA of $3.1 million.
The company raised its FY2025 guidance, now expecting Adjusted EBITDA of $1.0-$3.0 million and adjusted loss per share of $0.34-$0.38. Gross margin was 54.8%, with Med Tech gross margin at 63.7% and Med Device at 47.8%.
AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jim Clemmer, President and CEO, and Stephen Trowbridge, Executive VP and CFO, will deliver a presentation at the conference on Thursday, January 16, 2025, at 7:30 a.m. PT.
The presentation will be available as a live webcast through the company's investor relations section on their website, with a replay option available after the event. AngioDynamics focuses on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life.
AngioDynamics (NASDAQ: ANGO) has announced a virtual investor event scheduled for January 8, 2025, at 9:30am ET, following their Fiscal 2025 Second Quarter Financial Results Conference Call. The 60-minute event will showcase the company's NanoKnife™ System, featuring their proprietary irreversible electroporation (IRE) technology.
The presentation will focus on how the NanoKnife System is positioned to become the standard, function-preserving treatment for men with prostate tumors. Leaders from the company's Oncology division will discuss the system's unique mechanism of action, patient care impact, physician and patient advocacy group collaborations, and its market opportunity and commercialization strategy.
AngioDynamics, a medical technology company, specializes in restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life.
AngioDynamics (NASDAQ: ANGO) has announced it will release its fiscal 2025 second quarter financial results on January 8, 2025, before market open. The company will host two key events on the same day: a financial results conference call at 8:00 AM ET and a Virtual NanoKnife System investor event at 9:30 AM ET.
The conference call will be accessible via phone (1-877-407-0784 domestic, +1-201-689-8560 international) and webcast through the company's investor section website. A replay will be available until January 15, 2025, using passcode 13750571. The subsequent NanoKnife event aims to provide investors with deeper insights into the technology and company strategy.
